Datopotamab Deruxtecan, often abbreviated as DATO, represents the notable advancement in targeted cancer treatment. This innovative antibody-drug conjugate pairs a monoclonal antibody specifically focused on HER-2 https://prbookmarkingwebsites.com/story28218293/datopotamab-deruxtecan-the-promising-antibody-drug-conjugate